The use of homeopathy to treat depression in peri- and postmenopausal women seems widespread, but there is a lack of clinical trials testing its efficacy. The aim of this new study was therefore to assess efficacy and safety of individualized homeopathic treatment versus placebo and fluoxetine versus placebo in peri- and postmenopausal women with moderate to severe depression.
A randomized, placebo-controlled, double-blind, double-dummy, superiority, three-arm trial with a 6 week follow-up study was conducted. The study was performed in a Mexican outpatient service of homeopathy. One hundred thirty-three peri- and postmenopausal women diagnosed with major depression according to DSM-IV (moderate to severe intensity) were included. The outcomes were:
- the change in the mean total score among groups on the 17-item Hamilton Rating Scale for Depression,
- the Beck Depression Inventory;
- the Greene Scale, after 6 weeks of treatment,
- response rates,
- remission rates,
Efficacy data were analyzed in the intention-to-treat population (ANOVA with Bonferroni post-hoc test).
After a 6-week treatment, the results of homeopathic group showed more effectiveness than placebo in the Hamilton Scale. Response rate was 54.5% and remission rate was 15.9%. There was a significant difference between groups in response rate, but not in remission rate. The fluoxetine-placebo difference was 3.2 points. No differences were observed between groups in the Beck Depression Inventory. The results of the homeopathic group were superior to placebo regarding Greene Climacteric Scale (8.6 points). Fluoxetine was not different from placebo in the Greene Climacteric Scale.
The authors concluded that homeopathy and fluoxetine are effective and safe antidepressants for climacteric women. Homeopathy and fluoxetine were significantly different from placebo in response definition only. Homeopathy, but not fluoxetine, improves menopausal symptoms scored by Greene Climacteric Scale.
The article is interesting but highly confusing and poorly reported. The trial is small and short-term only. The way I see it, the finding that individualised homeopathy is better than a standard anti-depressant might be due to a range of phenomena:
- residual bias; (for instance, it is conceivable that some patients were ‘de-blinded’ due to the well-known side-effects of the conventional anti-depressant);
- inappropriate statistical analysis if the data;
- or the effectiveness of individualised homeopathy.
Even if the findings of this study turned out to be real, it would most certainly be premature to advise patients to opt for homeopathy. At the very minimum, we would need an independent replication of this study – and somehow I doubt that it would confirm the results of this Mexican trial.